Suppliers / Zhejiang Starry Pharmaceutical

Zhejiang Starry Pharmaceutical

China 25 employees Updated 9 July 2026

Zhejiang Starry Pharmaceutical is an API manufacturer based in China. It holds 4 active US drug master files and 7 valid CEPs across a filed portfolio of 6 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 6 September 2024 as NAI.

4
active US DMFs
7
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 6 September 2024 NAI US FDA
  • 2 August 2019 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Xianju, China Not on file
China, China 3007027206

What they file, and where

Molecule Regulators Docs
Iopamidol EDQM, US FDA 4
Iodixanol EDQM, SFDA (Saudi Arabia), US FDA 3
Iohexol EDQM, US FDA 3
Iopromide EDQM 1
Levofloxacin EDQM 1
Lohexol SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Iodixanol API Iohexol API Iopamidol API Iopromide API Levofloxacin API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Zhejiang Starry Pharmaceutical

Does Zhejiang Starry Pharmaceutical hold a US DMF or a CEP?
Zhejiang Starry Pharmaceutical holds 4 active US drug master files and 7 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Zhejiang Starry Pharmaceutical FDA-registered?
One site operated by Zhejiang Starry Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Zhejiang Starry Pharmaceutical's last inspection go?
The most recent inspection on record closed on 6 September 2024 as NAI (No Action Indicated: nothing objectionable was found). 2 inspections are on file.
Where does Zhejiang Starry Pharmaceutical manufacture?
2 registered sites are on record, in China (Xianju and China). Every site is listed on this page with the register it came from.
What does Zhejiang Starry Pharmaceutical make?
6 molecules are on record against Zhejiang Starry Pharmaceutical, including Iopamidol, Iodixanol, Iohexol and Iopromide. Each links through to that molecule's full manufacturer list.
Which regulators recognise Zhejiang Starry Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Starry Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 6 September 2024.

Comparable suppliers

Suzhou Ryway Biotech shares 4 molecules Zhejiang Taizhou Hisyn Pharmaceutical shares 3 molecules Divi's Laboratories shares 2 molecules GE Healthcare shares 2 molecules Zhejiang Haizhou Pharmaceutical shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates